Amgen to Present New Data on Autoimmune Diseases at ACR Convergence

Amgen says it will present new data across rare and other serious autoimmune diseases at ACR Convergence 2026. The Phase 3 OASIZ-301 study of dazodalibep in Sjögren's disease showed statistically significant results; the supplied text is truncated before the full finding.